Therefore, GLP-1 RAs and SGLT-2i are the first choice for combined treatment of Type 2 diabetes patients with cardiovascular disease or with cardiovascular risk factors, chronic kidney disease, and heart failure. This evidence concerns the gene GLP1R and heart failure.